Prevention

Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.

With more parents opting for non-medical exemptions from vaccination in some states, a new study highlights the health and financial costs of even small reductions in vaccination rates.

After Italy’s parliamentary decision to mandate vaccines, France health officials follow suit, requiring parents to vaccinate their children against 11 common illnesses starting in 2018.

The CDC has updated interim guidance for healthcare providers who are caring for pregnant women with potential exposure to Zika virus.

Researchers from Washington University, in St. Louis, find correlations between specific groups of intestinal viruses and the risk of type 1 diabetes.

Contagion® covered the 9th International AIDS Conference on HIV Science this week and much of the research presented at the conference made this week’s Top 5. Topics include: the successful use of oral Truvada in adolescents, a new long-acting two-drug injectable HIV regimen, and a closer look at humanized monoclonal antibody PRO 140 for HIV treatment. Additional Top 5 articles include coverage from the Biodefense World Summit, and lack of infant immunizations across the world.

Snigdha Vallabhaneni, MD, MPH, shares actions patients and their visitors can take to protect themselves from Candida auris.

Pedro Cahn, MD, explains the new formulation of raltegravir HD.

Due to concerns that the use of PrEP might hinder clinicians from detecting HIV in infected individuals or lead to the development of resistant strains of HIV, scientists studied how PrEP affects seroconversion after HIV is acquired.

A phase 2a clinical trial has found the dapivirine vaginal ring to be a safe and acceptable means for HIV prevention in adolescents, who showed notably high adherence when using the ring.

The NIH has released the findings of the first of 2 early-stage clinical trials on assessing the safety and effectiveness of HIV candidate vaccinations that support additional development of vaccines.

Phase 2 study finds that the use of daily oral Truvada as a means of HIV prevention is safe and acceptable.

Scientists make an interesting connection between bats and detecting undiscovered disease.

Peter Williams, PhD, discusses the LATTE-2 trial for HIV treatment.

Ariane van der Straten, PhD, MPH, explains the different attributes of administering pre-exposure prophylaxis via a HIV biomedical implant.

Universal health coverage comes at a price but can countries afford it?

Kenneth Mayer, MD, explains why tenofovir alafenamide may be the future of pre-exposure prophylaxis.